Roquefort Therapeutics (LON:COIL) Shares Up 0.5% – Here’s What Happened

Posted by James Quigley on Oct 12th, 2026

Roquefort Therapeutics plc (LON:COIL – Get Free Report)’s stock price rose 0.5% during mid-day trading on Monday. The company traded as high as GBX 6.85 and last traded at GBX 6.25. 6,342,298 shares traded hands during mid-day trading, an increase of 2,314% from the average session volume of 262,781 shares. The stock had previously closed at GBX 6.22.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Roquefort Therapeutics in a report on Monday, September 21st.

View Our Latest Analysis on COIL

Roquefort Therapeutics Trading Up 0.5%

The company has a debt-to-equity ratio of 8.18, a quick ratio of 3.07 and a current ratio of 0.63. The firm has a fifty day moving average price of GBX 8.39 and a 200 day moving average price of GBX 9.11. The company has a market cap of £26.67 million, a price-to-earnings ratio of -0.31 and a beta of 0.05.

Roquefort Therapeutics (LON:COIL – Get Free Report) last issued its earnings results on Monday, September 28th. The company reported GBX (1.66) earnings per share for the quarter. Roquefort Therapeutics had a negative return on equity of 18.71% and a negative net margin of 57,057.07%.

Insider Buying and Selling

In other news, insider Stephen Paul West acquired 261,437 shares of the firm’s stock in a transaction dated Monday, September 28th. The stock was bought at an average price of GBX 8 per share, with a total value of £20,914.96. 36.27% of the stock is currently owned by corporate insiders.

Roquefort Therapeutics Company Profile

(Get Free Report)

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.